Effects of caspofungin against Candida guilliermondii and Candida parapsilosis
- PMID: 16870764
- PMCID: PMC1538640
- DOI: 10.1128/AAC.00111-06
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis
Abstract
The in vitro activity of caspofungin (CAS) was investigated against 28 yeast isolates belonging to Candida albicans (n = 5), Candida guilliermondii (n = 10), and Candida parapsilosis (n = 13). CAS MICs obtained by broth dilution and Etest methods clearly showed a rank order of susceptibility to the echinocandin compound with C. albicans > C. parapsilosis > C. guilliermondii. Similarly, time-kill assays performed on selected isolates showed that CAS was fungistatic against C. albicans and C. parapsilosis, while it did not exert any activity against C. guilliermondii. In a murine model of systemic candidiasis, CAS given at doses as low as 1 mg/kg of body weight/day was effective at reducing the kidney burden of mice infected with either C. albicans or C. guilliermondii isolates. Depending on the isolate tested, mice infected with C. parapsilosis responded to CAS given at 1 and/or 5 mg/kg/day. However, the overall CFU reduction for C. guilliermondii and C. parapsilosis was approximately 100-fold less than that for C. albicans. Our study shows that CAS was active in experimental systemic candidiasis due to C. guilliermondii and C. parapsilosis, but this activity required relatively high drug dosages.
Figures








Similar articles
-
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.J Clin Microbiol. 2006 Mar;44(3):760-3. doi: 10.1128/JCM.44.3.760-763.2006. J Clin Microbiol. 2006. PMID: 16517851 Free PMC article.
-
Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.J Clin Microbiol. 2001 Dec;39(12):4387-9. doi: 10.1128/JCM.39.12.4387-4389.2001. J Clin Microbiol. 2001. PMID: 11724849 Free PMC article.
-
Caspofungin in combination with amphotericin B against Candida parapsilosis.Antimicrob Agents Chemother. 2007 Mar;51(3):941-5. doi: 10.1128/AAC.00880-06. Epub 2006 Dec 11. Antimicrob Agents Chemother. 2007. PMID: 17158939 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
The echinocandins.Pharmacotherapy. 2007 Mar;27(3):369-88. doi: 10.1592/phco.27.3.369. Pharmacotherapy. 2007. PMID: 17316149 Review.
Cited by
-
Pharmacokinetic and pharmacodynamic considerations for antifungal therapy optimisation in the treatment of intra-abdominal candidiasis.Crit Care. 2023 Nov 20;27(1):449. doi: 10.1186/s13054-023-04742-w. Crit Care. 2023. PMID: 37981676 Free PMC article. Review.
-
Cellular apoptosis: An alternative mechanism of action for caspofungin against Candida glabrata.Curr Med Mycol. 2019 Jun;5(2):9-15. doi: 10.18502/cmm.5.2.1155. Curr Med Mycol. 2019. PMID: 31321332 Free PMC article.
-
Epidemiology of invasive candidiasis: a persistent public health problem.Clin Microbiol Rev. 2007 Jan;20(1):133-63. doi: 10.1128/CMR.00029-06. Clin Microbiol Rev. 2007. PMID: 17223626 Free PMC article. Review.
-
The Flo Adhesin Family.Pathogens. 2021 Oct 28;10(11):1397. doi: 10.3390/pathogens10111397. Pathogens. 2021. PMID: 34832553 Free PMC article. Review.
-
Candida sp. Infections in Patients with Diabetes Mellitus.J Clin Med. 2019 Jan 10;8(1):76. doi: 10.3390/jcm8010076. J Clin Med. 2019. PMID: 30634716 Free PMC article. Review.
References
-
- Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338. - PMC - PubMed
-
- Barchiesi, F., A. M. Schimizzi, A. W. Fothergill, G. Scalise, and M. G. Rinaldi. 1999. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 18:302-304. - PubMed
-
- Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332. - PMC - PubMed
-
- Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. - PubMed
-
- Di Bonaventura, G., I. Spedicato, C. Picciani, D. D'Antonio, and R. Piccolomini. 2004. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies. Antimicrob. Agents Chemother. 48:4453-4456. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources